<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Vancive Medical Technologies 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=20936></link><description><![CDATA[Vancive Medical Technologies 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Sat, 04 Apr 2026 23:46:14 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><language>ko-KR</language><item><title><![CDATA[Vancive Medical Technologies™, CareFusion Sign Agreement for Antimicrobial Dressing]]></title><link>https://www.newswire.co.kr/newsRead.php?no=723955</link><description><![CDATA[CHICAGO--(Business Wire/Korea Newswire)--Vancive Medical Technologies™ and CareFusion Corporation (NYSE:CFN) today announced an exclusive agreement in the United States, Canada and Mexico for the licensing and distribution of Vancive’s BeneHold™ Chlorhexidine Gluconate (CHG) antimicrobial Adhesive Technology for applications in vascular access.   Under the agreement, CareFusion will ma...]]></description><pubDate>Tue, 19 Nov 2013 21:00:00 +0900</pubDate></item><item><title><![CDATA[밴시브 메디컬 테크놀러지스™, 케어 퓨전과 향균 드레싱 계약 체결]]></title><link>https://www.newswire.co.kr/newsRead.php?no=723956</link><description><![CDATA[시카고--(Business Wire/뉴스와이어)--밴시브 메디컬 테크놀러지스 (Vancive Medical Technologies™)와 케어퓨전 코퍼레이션 (CareFusion Corporation, 뉴욕증권거래소:CFN)는 오늘 혈관 통로에 적용하는 밴시브의 베네홀드 (BeneHold™) 클로르헥시딘 글루코네이트(Chlorhexidine gluconate)(이하 CHG) 향균성 접착 기술 사용승인 및 유통과 관련, 미국, 캐나다와 멕시코에서 독점계약을 체결했다고 밝혔다.  본 ...]]></description><pubDate>Tue, 19 Nov 2013 21:00:00 +0900</pubDate></item></channel></rss>